Download PDF
Thromb Haemost 2017; 117(10): 1836-1839
DOI: 10.1160/TH17-07-0495
Invited Editorial Focus
Schattauer GmbH

Risk stratification with the DAPT score: Carefully read the instructions and use as intended

Davide Capodanno
1   Division of Cardiology, Cardio-Thoracic-Vascular Department, Azienda Ospedaliero-Universitaria “Policlinico-Vittorio Emanuele”, University of Catania, Catania, Italy
› Author Affiliations
Further Information

Publication History

Received: 21 July 2017

Accepted after major revision: 21 July 2017

Publication Date:
07 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Montalescot G, Brieger D, Dalby AJ. et al. Duration of dual antiplatelet therapy after coronary stenting: A review of the evidence. J Am Coll Cardiol 2015; 66: 832-847.
    CrossrefPubMedGoogle Scholar
  • 2 Vries MJA, van der Meijden PEJ, Henskens YMC. et al. Assessment of bleeding risk in patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost 2015; 115: 7-24.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Levine GN, Bates ER, Bittl JA. et al. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease. J Thorac Cardiovasc Surg 2016; 152: 1243-1275.
    CrossrefPubMedGoogle Scholar
  • 4 The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) 2014 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J 2014; 35: 2541-2619.
    CrossrefPubMedGoogle Scholar
  • 5 Capodanno D, Angiolillo DJ. Tailoring duration of DAPT with risk scores. Lancet 2017; 389: 987-989.
    CrossrefPubMedGoogle Scholar
  • 6 Yeh RW, Secemsky EA, Kereiakes DJ. et al. Development and validation of a prediction rule for benefit and harm of Dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. J Am Med Assoc 2016; 315: 1735-1749.
    CrossrefPubMedGoogle Scholar
  • 7 Mauri L, Kereiakes DJ, Yeh RW. et al. [DAPT] Twelve or 30 Months of Dual Antiplatelet Therapy after Drug-Eluting Stents. N Engl J Med 2014; 371: 2155-2166.
    CrossrefPubMedGoogle Scholar
  • 8 Kittelson JM, Steg PG, Halperin JL. et al. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thromb Haemost 2016; 116: 544-553.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Lip GYH, Lane DA. Bleeding risk assessment in atrial fibrillation: observations on the use and misuse of bleeding risk scores. J Thromb Haemost 2016; 14: 1711-1714.
    CrossrefPubMedGoogle Scholar
  • 10 Chai-Adisaksopha C, Hillis C, Monreal M. et al. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding A meta-analysis. Thromb Haemost 2015; 114: 819-825.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Roldan V, Marín F. Assessment of bleeding risk in acute ill medical patients An essential part of venous thromboembolism prevention. Thromb Haemost 2016; 116: 403-404.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 12 Harada Y, Michel J, Lohaus R. et al. Validation of the DAPT score in patients randomized to 6 or 12 months clopidogrel after predominantly second-generation drug-eluting stents. Thromb Haemost 2017; 117: 1989-1999.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Steg PG, Mehta SR, Jukema JW. et al. RUBY-1: A randomized, double-blind, placebo-controlled trial of the safety and tolerability of the novel oral factor Xa inhibitor darexaban (YM150) following acute coronary syndrome. Eur Heart J 2011; 32: 2541-2554.
    CrossrefPubMedGoogle Scholar
  • 14 Piccolo R, Gargiulo G, Franzone A. et al. Use of the Dual-Antiplatelet Therapy Score to Guide Treatment Duration After Percutaneous Coronary Intervention. Ann Intern Med 2017; 348: g3859.
    PubMedGoogle Scholar
  • 15 Kietzmann T. Myocardial infarction in elderly patients: How to assess their bleeding risk?. Thromb Haemost 2015; 114: 869-871.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 16 Didier R, Morice MC, Barragan P. et al. 6– Versus 24-Month Dual Antiplatelet Therapy After Implantation of Drug-Eluting Stents in Patients Nonresistant to Aspirin. JACC Cardiovasc Interv 2017; 10: 1202-1210.
    CrossrefPubMedGoogle Scholar
  • 17 Nakamura M, Iijima R, Ako J. et al. Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation. JACC Cardiovasc Interv 2017; 10: 1189-1198.
    CrossrefPubMedGoogle Scholar